Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 13/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600085 | 0.75 | EZH2 (0.33) | ALDH1A1HPGDMAPTKDM4EGAA | |
| SCHEMBL3594627 | 0.75 | PARP1 (0.32) | MAOAALDH1A1HPGDKDM4E | |
| SCHEMBL4087620 | 0.73 | TDP1 (0.42) | TDP1MAOAALDH1A1HPGDMAPT | |
| SCHEMBL3605401 | 0.68 | MAOA (0.41) | MAOAALDH1A1HPGDMAPTMAOB | |
| SCHEMBL3605365 | 0.68 | MAOA (0.41) | MAOAALDH1A1HPGDMAPTMAOB | |
| SCHEMBL3604223 | 0.67 | — | — | |
| SCHEMBL8802786 | 0.62 | ALDH1A1 (0.38) | ALDH1A1HPGDKDM4E | |
| SCHEMBL3601616 | 0.62 | MAOA (0.44) | MAOAALDH1A1HPGDMAPTMAOB | |
| SCHEMBL27702758 | 0.62 | ALDH1A1 (0.49) | TDP1MAOAALDH1A1HPGDMAPT | |
| SCHEMBL11506396 | 0.62 | TDP1 (0.53) | TDP1MAOAALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | CNR1, CNR2, GPR18 | TDP1 4817/4885MAOA 1094/4885ALDH1A1 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.